What is Columbus Circle Capital Corp II 's market cap?

Columbus Circle Capital Corp II (CMII) has a market capitalization of $317.4M and trades on XNAS.

Who are Columbus Circle Capital Corp II 's competitors?

Columbus Circle Capital Corp II 's key competitors include Quanterix Corporation, Nautilus Biotechnology, Inc., Seer, Inc., and others. These companies compete in similar markets and product categories.

Who does Columbus Circle Capital Corp II partner with?

Columbus Circle Capital Corp II 's notable partners include Illumina, Inc., Novartis Pharma AG, Amgen Inc., and others.

What subsidiaries does Columbus Circle Capital Corp II have?

Columbus Circle Capital Corp II 's subsidiaries include Palamedrix, Inc., SomaLogic Operating Co., Inc..

Where is Columbus Circle Capital Corp II headquartered?

Columbus Circle Capital Corp II is headquartered in United States of America. It has been publicly traded since 2026.

CMI

Columbus Circle Capital Corp II

CMII

SomaLogic is a leading commercial-stage proteomics company that provides an integrated platform for high-throughput protein analysis.

Market cap

$317.39M+2.9%

Table of contents

Competitors

By market cap

Thermo Fisher Scientific$189.58B+17.0%

TEC

Bio-Techne$11.1B+32.7%

Charles River Laboratories$10.8B+39.8%

CMI

Columbus Circle Capital Corp II $317.4M—

Nautilus Biotechnology, Inc.$226.2M+119%

Quantum-Si Incorporated$198.7M-49.4%

Quanterix Corporation$182.3M-32.8%

Seer, Inc.$119.9M-10.3%

By revenue growth

Quanterix Corporation+6.9%

Thermo Fisher Scientific+2.4%

TEC

Bio-Techne+0.2%

Charles River Laboratories+0.1%

By net margin

Thermo Fisher Scientific15.19%+0.4pp

TEC

Bio-Techne10.89%-0.7pp

Charles River Laboratories-4.59%-11.1pp

Quanterix Corporation-71.86%-36.6pp

Profile

SomaLogic is a leading commercial-stage proteomics company that provides an integrated platform for high-throughput protein analysis. The company leverages proprietary SOMAmer reagents and the SomaScan assay to deliver broad proteome coverage and precision for discovery, research, and clinical applications. Its value proposition is built on one of the world's largest proteomics databases and AI-driven bioinformatics to power diagnostic product development.

Competitive position

SomaLogic maintains a significant competitive position through its proprietary aptamer technology and a massive proteomics database containing over 4.2 billion protein measurements.

GeographiesUnited States, Japan, Europe, United Kingdom

Customer segmentsBiopharmaceutical companies, Academic institutions, Government agencies, Healthcare providers

Business modelAssay services, Product sales, Licensing and Royalties, Collaboration

SuppliersMicroarray readout system suppliers, Streptavidin bead suppliers, Automated liquid handling instrument manufacturers, DNA nanotechnology innovators

CustomersDrug discovery researchers, Clinical trial managers, Health systems, Diagnostic laboratories

CountryUnited States of America

Listed2026

CEOGary Quin

SectorFinancial Services

IndustryShell Companies

Websiteii.cmlifesciencesspac.com

FilingsSEC EDGAR

Questions, answered.

What is Columbus Circle Capital Corp II 's market cap?: Columbus Circle Capital Corp II (CMII) has a market capitalization of $317.4M and trades on XNAS.
Who are Columbus Circle Capital Corp II 's competitors?: Columbus Circle Capital Corp II 's key competitors include Quanterix Corporation, Nautilus Biotechnology, Inc., Seer, Inc., and others. These companies compete in similar markets and product categories.
Who does Columbus Circle Capital Corp II partner with?: Columbus Circle Capital Corp II 's notable partners include Illumina, Inc., Novartis Pharma AG, Amgen Inc., and others.
What subsidiaries does Columbus Circle Capital Corp II have?: Columbus Circle Capital Corp II 's subsidiaries include Palamedrix, Inc., SomaLogic Operating Co., Inc..
Where is Columbus Circle Capital Corp II headquartered?: Columbus Circle Capital Corp II is headquartered in United States of America. It has been publicly traded since 2026.